vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Paymentus Holdings, Inc. (PAY). Click either name above to swap in a different company.
Paymentus Holdings, Inc. is the larger business by last-quarter revenue ($330.5M vs $180.9M, roughly 1.8× AVANOS MEDICAL, INC.). Paymentus Holdings, Inc. runs the higher net margin — 6.3% vs -0.7%, a 7.0% gap on every dollar of revenue. On growth, Paymentus Holdings, Inc. posted the faster year-over-year revenue change (28.1% vs 0.7%). Paymentus Holdings, Inc. produced more free cash flow last quarter ($45.0M vs $21.3M). Over the past eight quarters, Paymentus Holdings, Inc.'s revenue compounded faster (33.7% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Paymentus Holdings, Inc. is a leading cloud-based bill payment and customer engagement technology provider. It offers integrated digital payment solutions, billing automation tools, and self-service portals for enterprises across utilities, financial services, government, healthcare, and telecommunications segments, primarily operating in the North American market.
AVNS vs PAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $330.5M |
| Net Profit | $-1.3M | $20.7M |
| Gross Margin | 47.5% | 25.4% |
| Operating Margin | 1.4% | 7.3% |
| Net Margin | -0.7% | 6.3% |
| Revenue YoY | 0.7% | 28.1% |
| Net Profit YoY | 99.7% | 57.2% |
| EPS (diluted) | $-0.02 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $330.5M | ||
| Q3 25 | $177.8M | $310.7M | ||
| Q2 25 | $175.0M | $280.1M | ||
| Q1 25 | $167.5M | $275.2M | ||
| Q4 24 | $179.6M | $257.9M | ||
| Q3 24 | $170.4M | $231.6M | ||
| Q2 24 | $171.7M | $197.4M | ||
| Q1 24 | $166.1M | $184.9M |
| Q4 25 | $-1.3M | $20.7M | ||
| Q3 25 | $-1.4M | $17.7M | ||
| Q2 25 | $-76.8M | $14.7M | ||
| Q1 25 | $6.6M | $13.8M | ||
| Q4 24 | $-397.3M | $13.1M | ||
| Q3 24 | $4.3M | $14.4M | ||
| Q2 24 | $1.8M | $9.4M | ||
| Q1 24 | $-900.0K | $7.2M |
| Q4 25 | 47.5% | 25.4% | ||
| Q3 25 | 48.4% | 24.1% | ||
| Q2 25 | 52.6% | 25.5% | ||
| Q1 25 | 53.6% | 24.0% | ||
| Q4 24 | 54.6% | 25.6% | ||
| Q3 24 | 54.5% | 26.2% | ||
| Q2 24 | 55.7% | 29.8% | ||
| Q1 24 | 57.1% | 28.5% |
| Q4 25 | 1.4% | 7.3% | ||
| Q3 25 | 0.1% | 6.4% | ||
| Q2 25 | -42.6% | 5.7% | ||
| Q1 25 | 6.1% | 5.7% | ||
| Q4 24 | -233.0% | 5.5% | ||
| Q3 24 | 7.0% | 5.2% | ||
| Q2 24 | 3.7% | 5.2% | ||
| Q1 24 | 2.4% | 4.5% |
| Q4 25 | -0.7% | 6.3% | ||
| Q3 25 | -0.8% | 5.7% | ||
| Q2 25 | -43.9% | 5.3% | ||
| Q1 25 | 3.9% | 5.0% | ||
| Q4 24 | -221.2% | 5.1% | ||
| Q3 24 | 2.5% | 6.2% | ||
| Q2 24 | 1.0% | 4.7% | ||
| Q1 24 | -0.5% | 3.9% |
| Q4 25 | $-0.02 | $0.16 | ||
| Q3 25 | $-0.03 | $0.14 | ||
| Q2 25 | $-1.66 | $0.11 | ||
| Q1 25 | $0.14 | $0.11 | ||
| Q4 24 | $-8.64 | $0.11 | ||
| Q3 24 | $0.09 | $0.11 | ||
| Q2 24 | $0.04 | $0.07 | ||
| Q1 24 | $-0.02 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $320.9M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $560.4M |
| Total Assets | $1.1B | $667.9M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $320.9M | ||
| Q3 25 | $70.5M | $287.9M | ||
| Q2 25 | $90.3M | $266.4M | ||
| Q1 25 | $97.0M | $245.8M | ||
| Q4 24 | $107.7M | $205.9M | ||
| Q3 24 | $89.0M | $187.5M | ||
| Q2 24 | $92.2M | $188.8M | ||
| Q1 24 | $75.8M | $180.1M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $560.4M | ||
| Q3 25 | $778.0M | $537.4M | ||
| Q2 25 | $776.3M | $516.7M | ||
| Q1 25 | $839.4M | $500.4M | ||
| Q4 24 | $828.5M | $485.6M | ||
| Q3 24 | $1.2B | $468.8M | ||
| Q2 24 | $1.2B | $451.6M | ||
| Q1 24 | $1.2B | $439.4M |
| Q4 25 | $1.1B | $667.9M | ||
| Q3 25 | $1.1B | $644.4M | ||
| Q2 25 | $1.0B | $609.5M | ||
| Q1 25 | $1.1B | $590.9M | ||
| Q4 24 | $1.2B | $576.2M | ||
| Q3 24 | $1.7B | $552.9M | ||
| Q2 24 | $1.7B | $527.7M | ||
| Q1 24 | $1.7B | $514.0M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $45.1M |
| Free Cash FlowOCF − Capex | $21.3M | $45.0M |
| FCF MarginFCF / Revenue | 11.8% | 13.6% |
| Capex IntensityCapex / Revenue | 3.8% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 2.18× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $161.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $45.1M | ||
| Q3 25 | $14.0M | $35.1M | ||
| Q2 25 | $6.8M | $31.5M | ||
| Q1 25 | $25.7M | $50.4M | ||
| Q4 24 | $57.9M | $27.9M | ||
| Q3 24 | $23.0M | $6.7M | ||
| Q2 24 | $27.8M | $18.0M | ||
| Q1 24 | $-8.0M | $11.0M |
| Q4 25 | $21.3M | $45.0M | ||
| Q3 25 | $7.0M | $35.0M | ||
| Q2 25 | $-4.2M | $31.4M | ||
| Q1 25 | $19.0M | $50.4M | ||
| Q4 24 | $53.1M | $27.8M | ||
| Q3 24 | $20.0M | $6.7M | ||
| Q2 24 | $21.9M | $17.8M | ||
| Q1 24 | $-12.1M | $10.8M |
| Q4 25 | 11.8% | 13.6% | ||
| Q3 25 | 3.9% | 11.3% | ||
| Q2 25 | -2.4% | 11.2% | ||
| Q1 25 | 11.3% | 18.3% | ||
| Q4 24 | 29.6% | 10.8% | ||
| Q3 24 | 11.7% | 2.9% | ||
| Q2 24 | 12.8% | 9.0% | ||
| Q1 24 | -7.3% | 5.9% |
| Q4 25 | 3.8% | 0.0% | ||
| Q3 25 | 3.9% | 0.0% | ||
| Q2 25 | 6.3% | 0.0% | ||
| Q1 25 | 4.0% | 0.0% | ||
| Q4 24 | 2.7% | 0.0% | ||
| Q3 24 | 1.8% | 0.0% | ||
| Q2 24 | 3.4% | 0.1% | ||
| Q1 24 | 2.5% | 0.1% |
| Q4 25 | — | 2.18× | ||
| Q3 25 | — | 1.98× | ||
| Q2 25 | — | 2.14× | ||
| Q1 25 | 3.89× | 3.65× | ||
| Q4 24 | — | 2.12× | ||
| Q3 24 | 5.35× | 0.47× | ||
| Q2 24 | 15.44× | 1.93× | ||
| Q1 24 | — | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
PAY
| Payment Transaction Processing Revenue | $326.9M | 99% |
| Other | $3.5M | 1% |
